Other reported differences between the two patient populations (i.e. more participants with HR+/HER2– breast cancer reported vaginal dryness, mouth sores/ulcers, and headaches than participants with TNBC) speak to the heterogeneity of symptom presentation and classes of treatment deployed between these populations. This evidence concerns the gene ERBB2 and breast carcinoma.